Please see our guidance document on Retention and Market Share Claims and the P.A.A.B.: Supplementary Guideline for Market Share Claims in Advertising. Market share data should be the most current, since the various market factors that can impact market share are very dynamic. As such, the most recently-available data collected by an authoritative recognized independent source that is reflective of the Canadian market place should be used at the time of renewal.
-
223 - Hi, In the past we produced a branded APS presenting ongoing off-label trials. This piece was reviewed and approved by PAAB. Recently, we looked at the PAAB code and found that mentions of ongoing trials were acceptable in a non-promotional context. We have 2 questions: 1. Did the code change regarding the mention of ongoing trials? 2. Can you describe or give an example of a non-promotional context (unbranded material?)? Thank you
• Jennifer Carroll -
713 - Can ongoing studies for a group of products (same therapeutic category) be discussed in a Corporate APS, or must this be done in individual branded APS? For example, a company has a portfolio of diabetes drugs that with ongoing research into weight loss indications, and would like to produce a single piece discussing all trials.
• Jennifer Carroll -
601 - I have a question regarding MOA and Code Section 3.1. Suppose a TMA states that Product-X targets receptors A & B, with no additional information/limitations. It is known that Product-X also targets receptors D & E, although this information does not explicitly appear in the TMA (as it is not intended to be a repository of product information). Why would this additional information not be allowed under s3.1? We have seen s3.1 interpreted differently when applied to different sections of a TMA (eg. MOA has a highly conservative approach whereas other sections have greater latitude). Thank you.
• Jennifer Carroll